4. As of noon trading, Illumina ( ILMN) is down $2.94 (-3.9%) to $73.33 on average volume. Thus far, 997,945 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $73.22-$76.25 after having opened the day at $75.83 as compared to the previous trading day's close of $76.27.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.3 billion and is part of the health care sector. The company has a P/E ratio of 99.9, above the S&P 500 P/E ratio of 17.7. Shares are up 34.6% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence